NN106 Cyto-C

Cytochrome C Oxidase: Biomarker in Newly Diagnosed Glioblastoma Multiforme

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor. These tumors are often aggressive and infiltrate surrounding brain tissue. Signs and symptoms are initially non-specific. They may include headaches, personality changes, nausea, and symptoms similar to that of a stroke. Worsening of symptoms is often rapid and can progress to unconsciousness.

This research study is being conducted to prospectively evaluate the hypothesis that the overall survival time of a subject with newly diagnosed GBM tumors, treated with standard of care therapy, is a function of the CcO enzymatic activity in the tumor. In particular, tumors with high CcO activity, are associated with shorter time of overall survival when compared to tumors with low CcO activity. Standard of care therapy consists of post-surgical radiation therapy with concurrent Temozolomide followed by up to 12 cycles of adjuvant Temozolomide.

NN106 is supported by NINDS (U01 NS093663).

Protocol Principal Investigator: 
Contact Information: 

CCC Project Managers: Timothy Leonard, Christina Desir, David Klements

DCC Project Coordinators: Tina Neill-Hudson, Michele Costigan

  • Griguer CE, Oliva CR, Coffey CS, Cudkowicz ME, Conwit RA, Gudjonsdottir AL, Ecklund DJ, Fedler JK, Neill-Hudson TM, Nabors LB, Benge M, Hackney JR, Chase M, Leonard TP, Patel T, Colman H, de la Fuente M, Chaudhary R, Marder K, Kreisl T, Mohile N, Chheda MG, McNeill K, Kumthekar P, Dogan A, Drappatz J, Puduvalli V, Kowalska A, Graber J, Gerstner E, Clark S, Salacz M, Markert J Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial. Neurooncology Advances2021 December 244(1)doi: 10.1093/noajnl/vdab1.
    PubMed: PMID:35088051